All you need to know about DRDO's new anti-COVID-19 drug 2-DG
The anti-Covid oral drug has been developed by the Defence Research and Development Organisation's (DRDO's) leading laboratory- Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories
- May 10, 2021,
- Updated May 10, 2021 3:01 PM IST
DRDO's new anti-Covid oral drug, 2-deoxy-D-glucose (2-DG), was recently granted emergency use approval by the Drug Controller General of India (DCGI) as an adjunct therapy in moderate cases of COVID-19. The 2-DG drug is expected to help hospitalised COVID-19 patients and reduce their supplemental oxygen dependence.
The anti-Covid oral drug has been developed by the Defence Research and Development Organisation's (DRDO's) leading laboratory- Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories.
The anti-COVID drug 2-DG has been developed in powder form and is ingested orally by dissolving it in water.(Edited by Mohammad Haaris Beg)
Also Read: DRDO's anti-COVID drug approved for emergency use
DRDO's new anti-Covid oral drug, 2-deoxy-D-glucose (2-DG), was recently granted emergency use approval by the Drug Controller General of India (DCGI) as an adjunct therapy in moderate cases of COVID-19. The 2-DG drug is expected to help hospitalised COVID-19 patients and reduce their supplemental oxygen dependence.
The anti-Covid oral drug has been developed by the Defence Research and Development Organisation's (DRDO's) leading laboratory- Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories.
The anti-COVID drug 2-DG has been developed in powder form and is ingested orally by dissolving it in water.(Edited by Mohammad Haaris Beg)
Also Read: DRDO's anti-COVID drug approved for emergency use